444264
MMP Inhibitor III
The MMP Inhibitor III, also referenced under CAS 927827-98-3, controls the biological activity of MMP. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.
Synonym(s):
MMP Inhibitor III
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
Quality Level
Assay
≥90% (TLC)
form
lyophilized solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
desiccated
color
off-white
solubility
DMSO: 5 mg/mL
shipped in
ambient
storage temp.
−20°C
General description
A homophenylalanine-hydroxamic acid based broad-spectrum cell-permeable, reversible inhibitor of matrix metalloproteinases (supplied as a racemic mixture). Inhibits MMP-1 (IC50 = 7.4 nM), MMP-2 (IC50 = 2.3 nM), MMP-3 (IC50 = 135 nM), MMP-7 (IC50 = 10-100 nM), and MMP-13 (IC50 = 1-10 nM).
Biochem/physiol Actions
Cell permeable: yes
Primary Target
MMP-1
MMP-1
Product does not compete with ATP.
Reversible: yes
Target IC50: 7.4 nM, 2.3 nM, 135 nM, 10-100 nM, 1-10 nM, against MMP-1, MMP-2, MMP-3, MMP-7, and MMP-13, respectively
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months (-20°C).
Other Notes
Covington, M.D., et al. 2006, Am. J. Physiol. Renal. Physiol.290, F43.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Journal of peptide science : an official publication of the European Peptide Society, 23(12), 845-854 (2017-10-24)
Bariatric surgery is currently the most effective treatment of obesity, which has spurred an interest in developing pharmaceutical mimetics. It is thought that the marked body weight-lowering effects of bariatric surgery involve stimulated secretion of appetite-regulating gut hormones, including glucagon-like
Inhibition of TGF-β signaling, invasion, and growth of cutaneous squamous cell carcinoma by PLX8394.
Oncogene, 42(49), 3633-3647 (2023-10-21)
Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer. The prognosis of patients with metastatic cSCC is poor emphasizing the need for new therapies. We have previously reported that the activation of Ras/MEK/ERK1/2 and transforming growth factor
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service